206 related articles for article (PubMed ID: 15057135)
1. Progress in the clinical development of new marine-derived anticancer compounds.
Jimeno J; López-Martín JA; Ruiz-Casado A; Izquierdo MA; Scheuer PJ; Rinehart K
Anticancer Drugs; 2004 Apr; 15(4):321-9. PubMed ID: 15057135
[TBL] [Abstract][Full Text] [Related]
2. Progress in the development and acquisition of anticancer agents from marine sources.
Amador ML; Jimeno J; Paz-Ares L; Cortes-Funes H; Hidalgo M
Ann Oncol; 2003 Nov; 14(11):1607-15. PubMed ID: 14581267
[No Abstract] [Full Text] [Related]
3. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
4. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
5. [Development of marine-derived anti-cancer compounds].
Taguchi T
Gan To Kagaku Ryoho; 2003 May; 30(5):579-88. PubMed ID: 12795086
[TBL] [Abstract][Full Text] [Related]
6. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
7. New drugs from the sea.
D'Incalci M; Simone M; Tavecchio M; Damia G; Garbi A; Erba E
J Chemother; 2004 Nov; 16 Suppl 4():86-9. PubMed ID: 15688619
[TBL] [Abstract][Full Text] [Related]
8. A clinical armamentarium of marine-derived anti-cancer compounds.
Jimeno JM
Anticancer Drugs; 2002 May; 13 Suppl 1():S15-9. PubMed ID: 12173490
[TBL] [Abstract][Full Text] [Related]
9. In vitro toxicity of three new antitumoral drugs (trabectedin, aplidin, and kahalalide F) on hematopoietic progenitors and stem cells.
Gómez SG; Bueren JA; Faircloth GT; Jimeno J; Albella B
Exp Hematol; 2003 Nov; 31(11):1104-11. PubMed ID: 14585376
[TBL] [Abstract][Full Text] [Related]
10. Marine-derived anticancer agents in clinical trials.
Schwartsmann G; Da Rocha AB; Mattei J; Lopes R
Expert Opin Investig Drugs; 2003 Aug; 12(8):1367-83. PubMed ID: 12882622
[TBL] [Abstract][Full Text] [Related]
11. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma.
Schöffski P; Wolter P; Clement P; Sciot R; De Wever I; Wozniak A; Stefan C; Dumez H
Future Oncol; 2007 Aug; 3(4):381-92. PubMed ID: 17661712
[TBL] [Abstract][Full Text] [Related]
12. In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. comparison with the clinical results.
Albella B; Faircloth G; López-Lázaro L; Guzmán C; Jimeno J; Bueren JA
Eur J Cancer; 2002 Jul; 38(10):1395-404. PubMed ID: 12091072
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives.
Gordon EM; Sankhala KK; Chawla N; Chawla SP
Adv Ther; 2016 Jul; 33(7):1055-71. PubMed ID: 27234989
[TBL] [Abstract][Full Text] [Related]
14. Editorial comment on "In vitro toxicity of ET-743 and Aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors: comparison with the clinical results" by Albella and colleagues.
D'Incalci M
Eur J Cancer; 2002 Jul; 38(10):1297. PubMed ID: 12091058
[No Abstract] [Full Text] [Related]
15. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
16. Adding pharmacogenomics to the development of new marine-derived anticancer agents.
Jimeno J; Aracil M; Tercero JC
J Transl Med; 2006 Jan; 4():3. PubMed ID: 16401350
[TBL] [Abstract][Full Text] [Related]
17. Ecteinascidin-743.
Held-Warmkessel J
Clin J Oncol Nurs; 2003; 7(3):313-9. PubMed ID: 12793338
[TBL] [Abstract][Full Text] [Related]
18. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
[TBL] [Abstract][Full Text] [Related]
19. Development of Yondelis (trabectedin, ET-743). A semisynthetic process solves the supply problem.
Cuevas C; Francesch A
Nat Prod Rep; 2009 Mar; 26(3):322-37. PubMed ID: 19240944
[TBL] [Abstract][Full Text] [Related]
20. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
Gennigens C; Jerusalem G
Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
